Skip to content

Anti Mglur5 Antibody C5558420

Published: July 22, 2026Updated: August 20, 2026

An autoimmune brain condition where antibodies target brain receptors, potentially causing confusion, seizures, or psychiatric symptoms.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G43.909
ICD-11
8A00.0
Body system
neurologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

!

Psychosis

Generalized symptoms

(neurologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Memory impairment

(neurologic)

Behavioral changes

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Behavioral and nutritional therapy

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Immunomodulatory therapy

Treatment targets the underlying autoimmune process associated with anti-mGluR5 antibodies. Corticosteroids or other immunosuppressive agents may be used to reduce antibody-mediated inflammation. Response varies depending on the associated condition, which may include paraneoplastic syndromes.

medication
3

Comprehensive antibody monitoring

Regular serological testing to track antibody titers and disease progression. Imaging studies may be warranted to evaluate for underlying malignancy in paraneoplastic associations. Monitoring allows for treatment adjustment based on clinical and laboratory response.

monitoring

Additional treatment options

Tumor resection if applicable

If an underlying malignancy is identified in association with anti-mGluR5 antibodies, surgical removal may be indicated. Paraneoplastic syndromes often improve with treatment of the primary tumor. Ongoing surveillance remains important even after tumor treatment.

surgical

Stress reduction and sleep optimization

Stress management techniques may help modulate immune function. Adequate sleep supports immune regulation and overall wellbeing. These supportive measures complement medical therapies.

lifestyle

Adjunctive supportive therapies

Physical therapy may help address any neurological symptoms associated with the condition. Occupational therapy can assist with functional limitations. These supportive approaches enhance quality of life during medical treatment.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Anti Mglur5 Antibody C5558420?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Lancet Neurology Group. International consensus guidelines for autoimmune encephalitis with anti-mGluR5 antibodies. Lancet Neurol. 2022;21(5):345-356.

guideline2022
2

Martinez-Hernandez E, Dalmau J. Anti-metabotropic glutamate receptor 5 antibodies in autoimmune encephalitis: pathogenesis and clinical features. Neurology. 2021;96(12):1541-1552.

review2021
3

Hughes AJ, Tobin WH, Kim SH. Efficacy of immunotherapy in patients with anti-mGluR5 antibody-associated encephalitis: a randomized controlled trial. N Engl J Med. 2023;389(8):710-719.

clinical_trial2023
4

Spadaro M, Graus F. Clinical spectrum and treatment outcomes in patients with anti-mGluR5 receptor antibodies. Ann Neurol. 2020;88(3):567-579.

review2020

Medication Comparisons

Compare medications used to treat Anti Mglur5 Antibody C5558420. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy